All In Biotech

Drug Trial Radar · NCT06840392

A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa

A Randomized, Double-blind, Double-dummy, Placebo-controlled, Multicenter, Phase 3 Study Assessing the Efficacy, Safety, and Tolerability of 2 Doses of Remibrutinib Over a 68-week Treatment Period in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa (RECHARGE-2)

Last checked: Nov 20, 2026Latest source record: Oct 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 565 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

565

Actual

Start

Mar 20, 2025

Primary completion

Jun 3, 2027

Study completion Oct 21, 2027

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Feb 21, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years, up to 100 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to establish the efficacy, safety, and tolerability of remibrutinib (LOU064) Dose A and Dose B compared to placebo in participants with moderate to severe hidradenitis suppurativa (HS).

Conditions

  • Hidradenitis Suppurativa

Interventions

  • Remibrutinib Dose ADrug

    Remibrutinib Dose A (oral)

  • Remibrutinib Dose BDrug

    Remibrutinib Dose B (oral)

  • Placebo 1Drug

    Placebo matching to remibrutinib Dose A (oral)

  • Placebo 2Drug

    Placebo matching to remibrutinib Dose B (oral)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of participants with Hidradenitis Suppurativa clinical response 50 (HiSCR50) at Week 16Time frame: Week 16

Locations

129 sites in 19 countries. Site status is shown where the registry gives one.

  • Total Skin and Beauty Dermatology Center PC

    Birmingham, Alabama

  • CTT Research

    Gilbert, Arizona

  • Ctr for Dermatology Clinical Res

    Fremont, California

  • USC Keck School of Medicine

    Los Angeles, California

  • MedDerm Associates

    San Diego, California

  • Driven Research

    Miami, Florida

  • Floridian Research Institute

    Miami, Florida

  • Sarasota Arthritis Res Ctr

    Sarasota, Florida

  • University Of South Florida

    Tampa, Florida

  • Emory School of Med Dermatology

    Atlanta, Georgia

  • Atlanta Biomedical Clin Res LLC

    Atlanta, Georgia

  • Northwestern University

    Chicago, Illinois

  • Endeavor Health

    Glenview, Illinois

  • Dundee Dermatology

    West Dundee, Illinois

  • Southern IN Clinical Trials

    New Albany, Indiana

  • Beth Israel Deaconess Med Center

    Boston, Massachusetts

  • Metro Boston Clinical Partners

    Brighton, Massachusetts

  • Clinical Research Inst of MI

    Chesterfield, Michigan

  • Deluxe Dermatology

    St Louis, Missouri

  • Skin Specialists PC

    Omaha, Nebraska

  • Vivida Dermatology

    Las Vegas, Nevada

  • North Shore University Hospital

    New Hyde Park, New York

  • Cameron Dermatology

    New York, New York

  • Optima Research Boardman

    Boardman, Ohio

  • Ohio State University

    Columbus, Ohio

  • Wright State University

    Fairborn, Ohio

  • Apex Clinical Research Center LLC

    Mayfield Heights, Ohio

  • Clinical Research Ctr of Carolinas

    Charleston, South Carolina

  • Goodlettsville Dermatology Research

    Goodlettsville, Tennessee

  • Accurate Clinical Research

    Humble, Texas

  • Austin Inst for Clinical Research

    Pflugerville, Texas

  • Center for Clinical Studies-Lee

    Webster, Texas

  • Care Access Alexandria

    Arlington, Virginia

  • Complexions Dermatology

    Danville, Virginia

  • Forefront Dermatology

    Vienna, Virginia

  • Novartis Investigative Site

    Caba, Argentina

  • Novartis Investigative Site

    CABA, Argentina

  • Novartis Investigative Site

    Córdoba, Córdoba Province, Argentina

  • Novartis Investigative Site

    Linz, Austria

  • Novartis Investigative Site

    Liège, Belgium

Showing 40 of 129 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.